Christopher Cannon/LinkedIn
Feb 16, 2026, 13:21
Christopher Cannon: Factor XIa Inhibition Reduces Stroke Risk in Non-Cardioembolic Stroke and High-Risk TIA
Christopher Cannon, Cardiologist at Brigham and Women’s Hospital, Editor-in-Chief of Harvard Heart Letter, shared a post on LinkedIn:
”Factor XIa inhibition works! When added to antiplatelet therapy for non-cardioembolic ischemic stroke or high-risk TIA, XIa inhibition significantly reduced stroke by 26%, with no significant increase in bleeding!”
Title: Next-Generation Factor XIa Cuts Recurrent Stroke Risk by 26%— Asundexian prevented repeat strokes without bleeding side effects
Authors: Nicole Lou
Read the Full Article on MedPage Today։
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 4, 2026, 18:08Anirban Sen Gupta: Dante Disharoon’s Research on PlateChek Featured on JTH April 2026 Cover
-
Apr 4, 2026, 18:06Domenico Girelli: WHO 2024 Guidelines Reveal Higher Global Anemia Burden and Epidemiological Shift
-
Apr 4, 2026, 18:04Fotios Barkas: Exploring The Bidirectional Relationship Between Frailty and Stroke
-
Apr 4, 2026, 17:56Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
-
Apr 4, 2026, 17:55Julian Kyoung-Ryul Chun: The Largest Dataset on Embolic Complications after AF Is Out
-
Apr 4, 2026, 17:54Marie Dragoy: Insights from Norway on Helicopter Emergency Services in Suspected Stroke Care
-
Apr 4, 2026, 17:53Julia Shapranova: Connecting Neuroscience with The Reality of Clinical Trials Leadership and Management at ESOC 2026
-
Apr 4, 2026, 17:51Filippo Cademartiri: The DECIDE Registry Tackles a Critical Gap In Cardiovascular Care
-
Apr 4, 2026, 17:51Rabiah Alnoshan: A Pactical, Bedside Focused Approach to Bleeding